<DOC>
	<DOCNO>NCT02099903</DOCNO>
	<brief_summary>It randomize prospective control study transcatheter renal denervation patient systolic heart failure secondary Chagas ' disease . The purpose study evaluate safety effectiveness renal denervation patient Chagas heart disease , due reduction renal systemic sympathetic activity .</brief_summary>
	<brief_title>Renal Denervation Patients With Heart Failure Secondary Chagas Disease</brief_title>
	<detailed_description>The activation sympathetic nervous system one main mechanism involve heart failure pathophysiology , well activation renin-angiotensin-aldosterone system . These compensatory mechanism initially beneficial , order restore adequate cardiac output . Their long-term activation , nevertheless , lead several deleterious effect cardiovascular system , direct myocite lesion , cardiac hypertrophy , myocardial ischemia , oxidative stress , cardiac arrhythmia myocite apoptosis , among others . It widely demonstrate modulation sympathetic nervous system important therapeutic target treatment systolic heart failure . Beta-blocker ACE inhibitor therapy main stem heart failure treatment demonstrate reduction morbidity mortality condition . Despite optimized medical treatment , heart failure carry poor prognosis . Surgical sympathectomy use decade ago treatment malignant hypertension show marked reduction arterial pressure . However , procedure aggressive lead long hospitalization recovery period , well several limit adverse effect . Recently , transcatheter renal denervation evolve promising less invasive technique , allow destruction renal nerve locate adventitia renal artery . The ablation procedure perform delivery radiofrequency energy tip catheter position renal artery , standard femoral artery catheterization , less morbid safe approach . Renal denervation test mainly patient resistant hypertension , among indication , promise result . The pathophysiological basis treatment hypertension , well heart failure , stand participation renal afferent efferent nerve maintenance elevate systemic vascular resistance . Activation efferent nerve lead excretion renin , aldosterone , angiotensin II , elevate norepinephrine level consequent retention salt water reduction renal blood flow . This mechanism also afferent renal nerve activation contribute elevation sympathetic tonus central nervous system . In animal model heart failure , renal denervation demonstrate improvement renal cardiac function . Initial clinical study suggest intervention safe potentially effective treatment heart failure human . Chagas heart disease prevalent cause heart failure Brazil share several pathophysiological aspect describe cause heart failure . Our aim evaluate safety effectiveness renal denervation systolic heart failure due Chagas Heart disease .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Chagas Disease</mesh_term>
	<mesh_term>Chagas Cardiomyopathy</mesh_term>
	<mesh_term>Heart Failure , Systolic</mesh_term>
	<criteria>1 . Patients ≥ 18 ≤ 70 year age chronic systolic heart failure , Chagas disease etiology . 2 . Two positive serology result Chagas two distinct method . 3 . NYHA ( New York Heart Association ) class II III . 4 . Patients treat maximum tolerated dos standard pharmacotherapy heart failure . 5 . LVEF ( Left Ventricular Ejection Fraction ) ≤ 40 % ( Simpson Method ) . 1 . Patients NYHA class I IV . 2 . Sustained ventricular tachycardia ( &gt; 30 sec ) hemodynamic compromise . 3 . Presence permanent pacemaker implantable defibrillator . 4 . Systolic blood pressure &lt; 90 mmHg . 5 . Heart beat &lt; 60 bpm rest . 6 . Advanced renal insufficiency ( estimate glomerular filtration rate ( GFR ) &lt; 30 ml/min/1.73 square meter ) . 7 . Patients plan cardiac surgery percutaneous revascularization . 8 . Other reason would preclude patient participate study ( comorbidities , life expectancy le 1 year ) . 9 . Unsuitable anatomy renal artery , renal stenosis previous treatment balloon stent . 10 . Refusal patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Heart Failure , Systolic</keyword>
	<keyword>Chagas Disease</keyword>
	<keyword>Chagas Cardiomyopathy</keyword>
	<keyword>Renal Denervation</keyword>
	<keyword>Irrigated Radiofrequency Catheter</keyword>
</DOC>